|Bid||0.00 x 800|
|Ask||0.00 x 1800|
|Day's range||49.10 - 51.49|
|52-week range||31.51 - 59.70|
|Beta (5Y monthly)||1.34|
|PE ratio (TTM)||19.28|
|Earnings date||03 Aug 2020 - 07 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||52.67|
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis (RA). The data demonstrate sustained efficacy and a consistent safety profile with up to 52 weeks of filgotinib treatment across RA patient populations. The new data are among 15 abstracts on filgotinib in RA that will be presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology 2020.
Diodes Incorporated (Nasdaq: DIOD), today announced several enhanced corporate governance measures and compensation practices.
The global coronavirus pandemic converged on Monday with social unrest roiling the U.S., as hopes for relaxing lockdowns were undercut by raucous protests that prompted several big cities to impose curfews.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Mark Genovese, MD, has been appointed Senior Vice President, Inflammation, with responsibility for overseeing the clinical development of the company’s investigational portfolio of treatments for inflammatory conditions.
Diodes Incorporated (Nasdaq: DIOD), today announced that it has entered into a new credit agreement that will provide a $670 million, three-year secured credit facility. The new facility makes available up to $520 million in a term loan, a $150 million revolving credit line and will be funded by a syndicate of banks.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone. The study demonstrated that patients in the 5-day remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017). The odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care were also favorable, trending toward but not reaching statistical significance (OR 1.31 [95% CI 0.88-1.95]; p=0.18). No new safety signals were identified with remdesivir across either treatment group. Gilead plans to submit the full data for publication in a peer-reviewed journal in the coming weeks.
President Donald Trump announced that the U.S. was revoking its support for the agency, the latest escalation in a battle that has seen the president accuse the WHO of being too beholden to Beijing.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from a single-arm, open-label Phase 1b trial of magrolimab, an investigational anti-CD47 monoclonal antibody, in combination with azacitidine in previously untreated patients with higher-risk myelodysplastic syndrome (MDS) and previously untreated patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, including patients with TP53-mutant AML, a high unmet need population. Results continue to support the clinical activity of magrolimab and azacitidine. The data were presented during an oral session at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting held from May 29-31 (Abstract 7057).
Kite, a Gilead Company (Nasdaq: GILD), today announced results from an interim analysis of ZUMA-5, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory indolent (slow growing) non-Hodgkin lymphoma (NHL) after at least two prior lines of therapy. After a single infusion of Yescarta, 93 percent of patients (n=96 evaluable for efficacy) responded, with 80 percent of patients achieving a complete response (CR) as assessed by an independent review committee. The data were presented in an oral session during the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting held from May 29-31 (Abstract 8008). The presentation has also been selected for a Highlights of the Day session as part of ASCO’s 2020 Virtual Scientific Program on Saturday, May 30 at 11:30 am ET. The Highlights sessions recap the most impactful science from the oral sessions.
Diodes Incorporated (Nasdaq: DIOD) today announced the AP7353 low dropout regulator, which offers a high power supply rejection ratio (PSRR) in a small package, meeting the need for voltage regulation in noise-sensitive, battery-operated devices such as wearables, portables, and connected sensors.
Diodes Incorporated (Nasdaq: DIOD) today announced the introduction of the PI3WVR626, a MIPI® D-PHY/C-PHY 2:1 switch that enables a single host device to interface with two MIPI compliant modules, helping engineers optimize the design of multi-camera cell phones and other personal computing devices.
Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline. The agreement will also provide ongoing funding to support Arcus’s research and development programs.
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
Diodes Incorporated (Nasdaq: DIOD) today announced the availability of the first in a new generation of discrete MOSFETs. The DMN3012LEG delivers increased efficiency in a smaller package to provide significant cost, power, and space savings in a wide variety of power conversion and control applications.
Diodes Incorporated (Nasdaq: DIOD), today announced that management will participate at the following virtual financial conferences.
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis (UC). Filgotinib 200 mg achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion of patients compared with placebo. Filgotinib 100 mg did not achieve statistically significant clinical remission at Week 10.
Diodes Incorporated (NASDAQ: DIOD) today announced the industry's first automotive AEC-Q100 grade 3 qualified 10Gbps USB-C® DisplayPort™ Alternate (DP-Alt) mode linear ReDriver™ IC. The DP-Alt mode allows the transfer of DisplayPort signals through a USB Type-C® connector. Supporting 8.1Gbps DP1.4 and the 10Gbps USB 3.2 specifications, the PI3DPX1207Q provides a transparent, protocol-agnostic ReDriver capability for a range of automotive applications including infotainment systems and cluster display panels.
All eyes were on Moderna, which sparked a big rally on Wall Street after announcing promising early trial data of a coronavirus vaccine that is the furthest along among U.S. biotechs in the race.